Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1

Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors

(2020) Alessio Annovazzi et al.   CLINICAL NUCLEAR MEDICINE

The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors

(2020) Angelo Castello et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors

(2020) Angelo Castello et al.   Cancers

Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications

(2020) Pierre Decazes et al.   Cancers

Update on tumor metabolism and patterns of response to immunotherapy

(2020) Angelo Castello et al.   The quarterly journal of nuclear medicine and molecular imaging

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

(2019) Xiaoyun Li et al.   Nature Reviews Clinical Oncology

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

(2019) Romain-David Seban et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Hyper-progressive Disease in Patients With Non–Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT

(2019) Angelo Castello et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab

(2019) Giovanni Rossi et al.   JOURNAL OF NUCLEAR MEDICINE

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma

(2018) Christos Sachpekidis et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

(2018) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma

(2018) Kimiteru Ito et al.   JOURNAL OF NUCLEAR MEDICINE

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

(2018) Vivek Verma et al.   Journal for ImmunoTherapy of Cancer

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

(2017) Hoda Anwar et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma

(2017) Steve Y. Cho et al.   JOURNAL OF NUCLEAR MEDICINE

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

(2014) Christos Sachpekidis et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER